Canada - français - Health Canada

sivem pharmaceuticals ulc - pioglitazone (chlorhydrate de pioglitazone) - comprimé - 15mg - pioglitazone (chlorhydrate de pioglitazone) 15mg - thiazolidinediones

Canada - français - Health Canada

sivem pharmaceuticals ulc - pioglitazone (chlorhydrate de pioglitazone) - comprimé - 30mg - pioglitazone (chlorhydrate de pioglitazone) 30mg - thiazolidinediones

Canada - français - Health Canada

sivem pharmaceuticals ulc - pioglitazone (chlorhydrate de pioglitazone) - comprimé - 45mg - pioglitazone (chlorhydrate de pioglitazone) 45mg - thiazolidinediones

Union européenne - français - EMA (European Medicines Agency)

actavis group ptc ehf   - chlorhydrate de pioglitazone - diabète sucré, type 2 - les médicaments utilisés dans le diabète - pioglitazone is indicated as second or third line treatment of type 2 diabetes mellitus as described below:as monotherapyin adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance. as dual oral therapy in combination withmetformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin. a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea. as triple oral therapy in combination withmetformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy. pioglitazone is also indicated for combination with insulin in type 2 diabetes mellitus adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance (see section 4. après l'initiation du traitement avec la pioglitazone, les patients doivent être examinés après 3 à 6 mois afin d'évaluer l'adéquation de la réponse au traitement (e. la réduction de l'hba1c). chez les patients qui ne parviennent pas à montrer une réponse adéquate, la pioglitazone doit être interrompu. À la lumière des risques potentiels avec un traitement prolongé, les prescripteurs doivent confirmer à la routine des examens que l'avantage de la pioglitazone est maintenu (voir la section 4.

Canada - français - Health Canada

pharmascience inc - pioglitazone (chlorhydrate de pioglitazone) - comprimé - 15mg - pioglitazone (chlorhydrate de pioglitazone) 15mg - thiazolidinediones

Canada - français - Health Canada

pharmascience inc - pioglitazone (chlorhydrate de pioglitazone) - comprimé - 30mg - pioglitazone (chlorhydrate de pioglitazone) 30mg - thiazolidinediones

Canada - français - Health Canada

pharmascience inc - pioglitazone (chlorhydrate de pioglitazone) - comprimé - 45mg - pioglitazone (chlorhydrate de pioglitazone) 45mg - thiazolidinediones

Canada - français - Health Canada

accord healthcare inc - pioglitazone (chlorhydrate de pioglitazone) - comprimé - 30mg - pioglitazone (chlorhydrate de pioglitazone) 30mg - thiazolidinediones

Canada - français - Health Canada

accord healthcare inc - pioglitazone (chlorhydrate de pioglitazone) - comprimé - 45mg - pioglitazone (chlorhydrate de pioglitazone) 45mg - thiazolidinediones

Canada - français - Health Canada

accord healthcare inc - pioglitazone (chlorhydrate de pioglitazone) - comprimé - 15mg - pioglitazone (chlorhydrate de pioglitazone) 15mg - thiazolidinediones